Jonatan Dewulf1, Christel Vangestel1,2, Yannick Verhoeven3, Jorrit De Waele3, Karen Zwaenepoel3,4, Peter A van Dam3,5, Filipe Elvas1, Tim Van den Wyngaert1,2. 1. Molecular Imaging Center Antwerp (MICA), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium. 2. Nuclear Medicine, Antwerp University Hospital, Drie Eikenstraat 655, B-2650 Edegem, Belgium. 3. Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Faculty of Medicine and Health Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium. 4. Laboratory of Pathological Anatomy, Antwerp University Hospital, Drie Eikenstraat 655, B-2650 Edegem, Belgium. 5. Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Drie Eikenstraat 655, B-2650 Edegem, Belgium.
Abstract
PURPOSE: The involvement of RANK/RANKL signaling in the tumor microenvironment (TME) in driving response or resistance to immunotherapy has only very recently been recognized. Current quantification methods of RANKL expression suffer from issues such as sensitivity, variability, and uncertainty on the spatial heterogeneity within the TME, resulting in conflicting reports on its reliability and limited use in clinical practice. Non-invasive molecular imaging using immuno-PET is a promising approach combining superior targeting specificity of monoclonal antibodies (mAb) and spatial, temporal and functional information of PET. Here, we evaluated radiolabeled anti-RANKL mAbs as a non-invasive biomarker of RANKL expression in the TME. EXPERIMENTAL DESIGN: Anti-human RANKL mAbs (AMG161 and AMG162) were radiolabeled with 89Zr using the bifunctional chelator DFO in high yield, purity and with intact binding affinity. After assessing the biodistribution in healthy CD-1 nude mice, [89Zr]Zr-DFO-AMG162 was selected for further evaluation in ME-180 (RANKL-transduced), UM-SCC-22B (RANKL-positive) and HCT-116 (RANKL-negative) human cancer xenografts to assess the feasibility of in vivo immuno-PET imaging of RANKL. RESULTS: [89Zr]Zr-DFO-AMG162 was selected as the most promising tracer for further validation based on biodistribution experiments. We demonstrated specific accumulation of [89Zr]Zr-DFO-AMG162 in RANKL transduced ME-180 xenografts. In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts. There was good visual agreement with tumor autoradiography and immunohistochemistry on adjacent slides, confirming these findings. CONCLUSIONS: [89Zr]Zr-DFO-AMG162 can detect heterogeneous RANKL expression in the TME of human cancer xenografts, supporting further translation of RANKL immuno-PET to evaluate tumor RANKL distribution in patients.
PURPOSE: The involvement of RANK/RANKL signaling in the tumor microenvironment (TME) in driving response or resistance to immunotherapy has only very recently been recognized. Current quantification methods of RANKL expression suffer from issues such as sensitivity, variability, and uncertainty on the spatial heterogeneity within the TME, resulting in conflicting reports on its reliability and limited use in clinical practice. Non-invasive molecular imaging using immuno-PET is a promising approach combining superior targeting specificity of monoclonal antibodies (mAb) and spatial, temporal and functional information of PET. Here, we evaluated radiolabeled anti-RANKL mAbs as a non-invasive biomarker of RANKL expression in the TME. EXPERIMENTAL DESIGN: Anti-humanRANKL mAbs (AMG161 and AMG162) were radiolabeled with 89Zr using the bifunctional chelator DFO in high yield, purity and with intact binding affinity. After assessing the biodistribution in healthy CD-1nude mice, [89Zr]Zr-DFO-AMG162 was selected for further evaluation in ME-180 (RANKL-transduced), UM-SCC-22B (RANKL-positive) and HCT-116 (RANKL-negative) humancancer xenografts to assess the feasibility of in vivo immuno-PET imaging of RANKL. RESULTS: [89Zr]Zr-DFO-AMG162 was selected as the most promising tracer for further validation based on biodistribution experiments. We demonstrated specific accumulation of [89Zr]Zr-DFO-AMG162 in RANKL transduced ME-180 xenografts. In UM-SCC-22B xenograft models expressing physiological RANKL levels, [89Zr]Zr-DFO-AMG162 imaging detected significantly higher signal compared to control [89Zr]Zr-DFO-IgG2 and to RANKL negative HCT-116 xenografts. There was good visual agreement with tumor autoradiography and immunohistochemistry on adjacent slides, confirming these findings. CONCLUSIONS: [89Zr]Zr-DFO-AMG162 can detect heterogeneous RANKL expression in the TME of humancancer xenografts, supporting further translation of RANKL immuno-PET to evaluate tumorRANKL distribution in patients.
Authors: Sant Chawla; Jean-Yves Blay; Piotr Rutkowski; Axel Le Cesne; Peter Reichardt; Hans Gelderblom; Robert J Grimer; Edwin Choy; Keith Skubitz; Leanne Seeger; Scott M Schuetze; Robert Henshaw; Tian Dai; Danielle Jandial; Emanuela Palmerini Journal: Lancet Oncol Date: 2019-11-06 Impact factor: 41.316
Authors: Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis Journal: Cancer Res Date: 2018-01-23 Impact factor: 12.701
Authors: Elizabeth Ahern; Heidi Harjunpää; Jake S O'Donnell; Stacey Allen; William C Dougall; Michele W L Teng; Mark J Smyth Journal: Oncoimmunology Date: 2018-02-14 Impact factor: 8.110
Authors: Pieterjan Debie; Chrystel Lafont; Michel Defrise; Inge Hansen; Danny M van Willigen; Fijs W B van Leeuwen; Rik Gijsbers; Matthias D'Huyvetter; Nick Devoogdt; Tony Lahoutte; Patrice Mollard; Sophie Hernot Journal: J Control Release Date: 2019-11-14 Impact factor: 9.776
Authors: Y Y Kong; H Yoshida; I Sarosi; H L Tan; E Timms; C Capparelli; S Morony; A J Oliveira-dos-Santos; G Van; A Itie; W Khoo; A Wakeham; C R Dunstan; D L Lacey; T W Mak; W J Boyle; J M Penninger Journal: Nature Date: 1999-01-28 Impact factor: 49.962
Authors: Steven R Cummings; Javier San Martin; Michael R McClung; Ethel S Siris; Richard Eastell; Ian R Reid; Pierre Delmas; Holly B Zoog; Matt Austin; Andrea Wang; Stepan Kutilek; Silvano Adami; Jose Zanchetta; Cesar Libanati; Suresh Siddhanti; Claus Christiansen Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245
Authors: Peter A van Dam; Yannick Verhoeven; Xuan B Trinh; An Wouters; Filip Lardon; Hans Prenen; Evelien Smits; Marcella Baldewijns; Martin Lammens Journal: Crit Rev Oncol Hematol Date: 2018-11-03 Impact factor: 6.312
Authors: Frederike Bensch; Michaël M Smeenk; Suzanne C van Es; Johan R de Jong; Carolina P Schröder; Sjoukje F Oosting; Marjolijn N Lub-de Hooge; C Willemien Menke-van der Houven van Oordt; Adrienne H Brouwers; Ronald Boellaard; Elisabeth G E de Vries Journal: Theranostics Date: 2018-07-30 Impact factor: 11.556
Authors: Jonatan Dewulf; Ivanna Hrynchak; Sarah Geudens; Isabel Pintelon; Christel Vangestel; José Sereno; Peter A van Dam; Antero J Abrunhosa; Filipe Elvas; Tim Van den Wyngaert Journal: Pharmaceutics Date: 2022-04-26 Impact factor: 6.525